Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
May 30, 2024 19:22 ET
|
Syncromune
SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Direct Digital Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DRCT
May 30, 2024 19:14 ET
|
The Rosen Law Firm PA
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Direct...
ELS LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Equity LifeStyle Properties, Inc. Investors to Inquire About Securities Class Action Investigation – ELS
May 30, 2024 19:07 ET
|
The Rosen Law Firm PA
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Equity...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Autodesk, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADSK
May 30, 2024 18:56 ET
|
The Rosen Law Firm PA
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Autodesk, Inc. (NASDAQ: ADSK) between June 1, 2023 and...
Hydreight Reports Record Topline(1) Revenue of $4.87M in Q1-2024 (YOY Increase of 33%)
May 30, 2024 18:30 ET
|
Hydreight Technologies Inc.
VANCOUVER, British Columbia and LAS VEGAS, May 30, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) ( TSXV: NURS )( OTCQB: HYDTF )( FSE: SO6 ), a fast-growing...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
May 30, 2024 18:05 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Goodness Growth Holdings to Complete Non-Brokered Private Placement to Support the Relocation of a Minnesota Dispensary
May 30, 2024 18:00 ET
|
Goodness Growth Holdings, Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access,...
O2Gold Closes First Tranche of Private Placement
May 30, 2024 18:00 ET
|
O2Gold Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 30, 2024 (GLOBE NEWSWIRE) -- O2Gold Inc. (NEX: OTGO.H) (“O2Gold” or the “Company”) is...
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024 17:55 ET
|
Myriad Genetics, Inc.
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved...